MAR 1 1 2009

510(k) Summary 510(k) Number K09

Sedecal, Inc.
SEDECAL SA
C/ Pelaya, 9 – 13
Pol. Ind. Río de Janeiro
28110 Algete, Madrid
España (Spain)
Tel.- +34 91 6280544
Fax.- +34 91 6280574

Date Prepared: January 30, 2009

Contact: Ma Luisa Gómez de Agüero, Quality and Regulatory Manager

1. Identification of the Device:


Proprietary-Trade Name: Sedecal Millennium Plus Digital Diagnostic X-Ray System **Classification Name:** Stationary x-ray system, Product Code 90 KPR and Solid State X-Ray


Imager (Flat Panel/Digital Imager) 90 MQB,


Common/Usual Name: Digital Stationary Diagnostic X-Ray System

2. Equivalent legally marketed device: Sedecal Millennium Digital K042876 and Sedecal X Plus LP Plus, K062335. Digital panels: Canon, K060433 (50C); K031633 (40C); K031447 (50G); K023750 (40G).

- 3. Indications for Use (intended use) These Digital Radiographic Systems are intended for use by a qualified/trained doctor or technician on both adult and pediatric subjects for taking diagnostic radiographic exposures of the skull, spinal column, chest, abdomen, extremities, and other body parts. Applications can be performed with the patient sitting, standing, or lying in the prone or supine position.
- 4. Description of the Device: These digital diagnostic x-ray systems consist of a tubehead and collimator assembly mounted on a U-Arm, along with a generator, generator control, and an x-ray table. Power ratings for the available generators are in the rage of 50 kw to 80 kW. Exposure voltage range varies from 40 125 KV or 40 150 kV with current of 300 100 mA. Exposure time is 1 ms 10 s. This device represents a new combination of already cleared Sedecal and Canon products.
- 5. Safety and Effectiveness, comparison to predicate device. The results of bench and test laboratory indicates that the new device is as safe and effective as the predicate devices.







Sedecal Millennium Plus Digital

6. Substantial Equivalence Chart

6. Substantial	Equivalence Chart		
Characteristic .	Sedecal Millennium LP	Sedecal X Plus LP Plus,	Sedecal Millennium Plus
	Digital, K042876	K062335.	Digital
Intended Use:	Intended for use by a	SAME	SAME
	qualified/trained doctor		
	or technician on both		
	adult and pediatric		
	subjects for taking		
	diagnostic radiographic		
	exposures of the skull,		
	spinal column, chest,		
	abdomen, extremities,		
	and other body parts.		
	Applications can be		
	performed with the		
	patient sitting, standing,		
	or lying in the prone or		
	supine position.		
Configuration	U-Arm, column mount,	U-Arm mount only	Column mount
	or Ceiling Suspension		
Positioning	Standard	Enhanced	Enhanced, same as X Plus
controls			LP Plus
Performance	21 CFR 1020.30	SAME	SAME
Standard			
Generator	High frequency made	SAME	SAME
	by Sedecal		
Collimator	Manual, Ralco	Manual, Ralco	Manual (Ralco) or
			Automatic (Huestis)
Image acquisition	Digital CANON 50G	Film	CANON panels, multiple
			models: 50C, 50G, 40C &
T1 1 0			40G
Electrical safety	Electrical Safety per	SAME	SAME
	IEC-60601. UL listed	<u></u>	

7. Conclusion

After analyzing bench and external laboratory testing to applicable standards, it is the conclusion of Sedecal Inc that the Sedecal Millennium Plus Digital Diagnostic X-Ray Systems are as safe and effective as the predicate device, have few technological differences, and has no new indications for use, thus rendering them substantially equivalent to the predicate devices.







Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

MAR 1 1 2009

Sedecal SA % Daniel Kamm, P.E. Principal Consultant Kamm & Associates 333 Milford Rd. DEERFIELD IL 60015

Re: K090279

Trade/Device Name: Sedecal Millennium Plus Digital Diagnostic X-Ray Systems

Regulation Number: 21 CFR 892.1680 Regulation Name: Stationary x-ray system

Regulatory Class: II Product Code: KPR Dated: February 1, 2009 Received: February 9, 2009

Dear Mr. Kamm:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the <u>Code of Federal Regulations</u>, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801; good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding os substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at one of the following numbers, based on the regulation number at the top of this letter.

21 CFR 876.xxx	(Gastroenterology/Renal/Urology)	(240) 276-0115
21 CFR 884.xxx	(Obstetrics/Gynecology)	(240) 276-0115
21 CFR 892.xxx	(Radiology)	(240) 276-0120
Other		(240) 276-0100

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometrics' (OSB's) Division of Postmarket Surveillance at 240-276-3474. For questions regarding the reporting of device adverse events (Medical Device Reporting (MDR)), please contact the Division of Surveillance Systems at 240-276-3464. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufactures, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/cdrh/industry.suppot/index.html.

(anine M. Morris

Sincerely yours

Acting Director, Division of Reproductive, Abdominal, and Radiological Devices

Office of Device Evaluation

Center for Devices and Radiological Health

Enclosure

Concurrence of CDRH, Office of Device Evaluation (ODE)

Division of Reproductive, Abdominal and

Radiological Devices

Page 1 of 1